RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects
Status:
Terminated
Trial end date:
2020-03-17
Target enrollment:
Participant gender:
Summary
This is a Phase 1, multicentric, open-label,two arms to assess and compare the effect of
single oral administration of MD1003 on the pharmacokinetic parameters in renal impaired
patients and healthy subjects with normal renal function.
The planned enrollment is 36 subjects (18 impaired patients and 18 healthy subjects).